Ascelia Pharma AB

Ascelia Pharma AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development. Mangoral is a novel contrast agent for MR-scans in Phase III clinical studies. Mangoral is developed to improve the visualisation of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com

Ascelia Pharma to present at Share Day (Aktiedagen) in Stockholm on 10 September 2019

Fri, Sep 06, 2019 08:00 CET

On 10th of September, Ascelia Pharma's CEO Magnus Corfitzen will present the latest development in the company at Operaterassen in Stockholm. The Share Day event (Aktiedagen) is organised by Swedish Shareholders' Association and Ascelia Pharma will start the presentation at 8.30am CET.The presentation can be followed live via: www.aktiespararna.se/tv/live Program and registration for the day can be found here: https://www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-4 For more information, please contact:Mikael Widell, IR & Communications

There are no items matching the current filter

There are no more items matching the current filter

About Us

Links

Ascelia Pharma to present at Share Day (Aktiedagen) in Stockholm on 10 September 2019

Media